Company intelligence / Profile preview

Contraline

Charlottesville, Virginia, United Statescontraline.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

Contraline has initiated a first-in-human clinical trial in Australia to assess the safety and effectiveness of its ADAM™ hydrogel implant for long-lasting, reversible male contraception. The device blocks sperm flow by being injected into the vas deferens via a minimally invasive procedure. Early results include successful implantation in patients; this represents the first clinical trial on a non-hormonal male contraceptive device in over two decades.

Therapeutic areas: Men's Health
Modalities: DeviceHydrogel-based drug delivery therapy
Industry: Implantable Medical Devices

Drug pipeline

1 asset

ADAM

Phase 1

Indications: Male contraception

Partnerships

Population Council (option-to-license agreement for male contraceptive technology)

Beyond the preview

Go deeper on Contraline.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Contraline.

Explore the full profile